A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics

Volumn 4, Issue 35-50, 2001, Pages 35-50

  Phillips, C J ^a   Gilmour, L ^a   Gale, R ^a   Palmer, M ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Beta interferon; Cost effectiveness; Cost utility analysis; Multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

EID: 0035055971     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200104035050     Document Type: Article

References (35)

1. MS: A CNS and systemic auto-immune disease
2. The current therapy of multiple sclerosis
3. Quality of life in multiple sclerosis in France, Germany and the United Kingdom
4. Burden of illness of multiple sclerosis: Part II: Quality of life
5. Quality of life in multiple sclerosis
6. Assessing the psychosocial impact of multiple sclerosis: Learning from research on rheumatoid arthritis
7. Quality of life among persons with multiple sclerosis and their caregivers
8. Treating the family with multiple sclerosis
9. Caregivers of people with multiple sclerosis: A survey in New Zealand
10. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
11. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
12. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis
13. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
14. A cost-utility analysis of interferon beta for multiple sclerosis
15. Treatment of multiple sclerosis with interferon b: An appraisal of cost-effectiveness and quality of life
16. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
17. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Final outcome of the randomized controlled trial
18. Costs and quality of life in multiple sclerosis. A cross-sectional observations study in the UK
19. EuroQol - A new facility for the measurement of health-related quality of life
20. Modelling valuations for EuroQol health states
21. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions
22. Estimating long-term cost savings from treatment of Alzheimer's disease
23. A neurological rating scale for use in multiple sclerosis
24. Outcomes assessment in multiple sclerosis clinical trials: A critical analysis
25. Long term treatment of multiple sclerosis with interferon-b may be cost effective
26. Quick and clean: Authoritative health technology assessment for local health care contracting